TheraRadar
Clinical-Stage Companies / PT Bio Farma

PT Bio Farma

Pre-Approval PRO BETA
35
Total Trials
15
Phase 3
15
Phase 2
0
Recruiting
379
Score

Pipeline by Phase

Phase 3
15
Phase 2
15
Phase 1
8

Therapeutic Focus

Safety Issues Healthy COVID-19 Immunogenicity Vaccine Reaction

Clinical Trials (35)

NCT05482295 Phase 3 NOT YET RECRUITING

Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III)

Started: 9/1/2025

NCT05482282 Phase 3 WITHDRAWN

Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma)

Started: 12/1/2025

NCT05546502 Phase 3 COMPLETED

Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children

Started: 10/9/2022

NCT05433285 Phase 3 COMPLETED

Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine

Started: 6/7/2022

NCT04185545 Phase 3 COMPLETED

Efficacy, Safety and Immunogenicity of Rotavirus RV3 Vaccine (Bio Farma) in Neonates

Started: 10/30/2020

NCT04071379 Phase 3 COMPLETED

Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B

Started: 10/13/2020

NCT04508075 Phase 3 COMPLETED

Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine

Started: 8/10/2020

NCT04051268 Phase 3 COMPLETED

Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)

Started: 3/2/2020

NCT01986335 Phase 3 COMPLETED

Protectivity and Safety of DTP/HB/Hib (Bio Farma) Vaccines in Infants, Batch Consistency, Multi Center Trial

Started: 8/1/2012

NCT05933278 Phase 2 COMPLETED

Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine

Started: 7/25/2023

NCT05727215 Phase 2 COMPLETED

Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years of Age

Started: 2/28/2023

NCT04741828 Phase 2 COMPLETED

Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian

Started: 5/3/2021

NCT05525208 Phase 2 COMPLETED

Booster Study of COVID-19 Protein Subunit Recombinant Vaccine

Started: 9/1/2022

NCT05313035 Phase 2 COMPLETED

Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine

Started: 4/13/2022

NCT03919578 Phase 2 COMPLETED

Protectivity and Safety Following Recombinant Hepatitis B Vaccine

Started: 9/11/2019

NCT05124340 Phase 2 COMPLETED

Safety and Tuberculin Conversion Following BCG Vaccination

Started: 12/1/2021

NCT03460405 Phase 2 COMPLETED

Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants

Started: 7/16/2018

NCT04183114 Phase 2 COMPLETED

Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)

Started: 9/3/2019

NCT03336593 Phase 2 COMPLETED

Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population

Started: 11/21/2017

NCT02093260 Phase 2 COMPLETED

Immunogenocity and Safety of Flubio (Influenza HA) Vaccine in Infants and Children (Bridging Study)

Started: 5/1/2014

NCT02095314 Phase 2 COMPLETED

Antibody Persistence, Immune Response and Safety After Doses of Pentabio Vaccine

Started: 3/1/2014

NCT02093273 Phase 2 COMPLETED

Evaluation on Immunogenicity and Safety Profile of Trivalent OPV (tOPV Bio Farma)

Started: 5/1/2013

NCT01986322 Phase 2 COMPLETED

Immunogenicity and Safety of DTP/HB/Hib (Bio Farma)Compared to DTP/HB Given Simultaneously With Hib(Registered)Vaccine

Started: 7/1/2011

NCT06690515 Phase 1 NOT YET RECRUITING

Phase I/II, Open Label, Randomized, Safety and Immunogenicity Following DTwP-Hepatitis B-Hib-IPV Vaccine (Bio Farma) in Indonesian Infants

Started: 3/1/2025

NCT05228613 Phase 1 COMPLETED

Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018

Started: 2/16/2022

NCT05067894 Phase 1 COMPLETED

Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine

Started: 12/10/2021

NCT04188223 Phase 1 COMPLETED

Safety and Immunogenicity Following Recombinant Hepatitis B (Bio Farma) Vaccine in Adults & Children

Started: 12/3/2019

NCT03462108 Phase 1 COMPLETED

Safety and Immunogenicity of Rotavirus (Bio Farma) Vaccine in Adults, Children & Neonates

Started: 4/9/2018

NCT03109600 Phase 1 COMPLETED

Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)

Started: 4/18/2017

NCT01977170 Phase 1 COMPLETED

Safety of Hib Vaccine (Bio Farma)

Started: 11/1/2010

NCT01977196 Phase 1 COMPLETED

The Safety and Immunogenicity of DTP/Hepatitis B 10ug Hib Vaccine (Bio Farma)

Started: 4/1/2011

NCT06114641 Phase 4 COMPLETED

Effectiveness & Safety of Ovine Enoxaparin Sodium to Originator Enoxaparin in Non-ST-Segment Elevation ACS Patients

Started: 6/1/2023

NCT06053853 Phase 4 COMPLETED

Post Marketing Surveillance of Diphtheria Antitoxin (DAT)

Started: 1/31/2023

NCT03680417 Phase 4 COMPLETED

Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children

Started: 11/16/2017

NCT03310073 Phase 4 COMPLETED

Immunogenicity and Safety Profile of Primary Dose of bOPV Bio Farma Given Simultaneously With Pentabio And IPV

Started: 7/1/2016

Drug Candidates

Enoxaparin sodium injection In-House Recombinant Hepatitis B (Bio Farma) vaccine Registered Hepatitis B vaccine recombinant (Engerix-B) SARS-CoV-2 Subunit Recombinant Protein Vaccine Recombinant Hepatitis B new Bulk vaccine DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine Recombinant Hepatitis B vaccine (Registered BioFarma) Pentabio SARS-CoV-2 subunit protein recombinant vaccine SARS-CoV-2 Protein Subunit Recombinant Vaccine
Activity Status: Active
Last Trial Started: 12/1/2025
Last Trial Ended: 12/30/2024
Trials (12 months): 2
Completed Trials: 32
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.